Back
Amicus Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
FOLD
Sponsored
Trump wins! Dow to 75,000? Details here
See the explosive "Document 20" details here.
Sell
44
FOLD
Amicus Therapeutics
Last Price:
10.10
Seasonality Move:
8.32%
7 Day Trial
ALL ACCESS PASS
$
7
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More HereAmicus Therapeutics Price Quote
$10.10
-0.28 (-2.7%)
(Updated: November 14, 2024 at 5:55 PM ET)
Amicus Therapeutics Key Stats
Sell
44
Amicus Therapeutics (FOLD)
is a Sell
Day range:
$10.30 - $10.66
52-week range:
$9.02 - $14.57
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.44
P/B ratio:
17.53%
Volume:
2.6M
Avg. volume:
2.6M
1-year change:
1.07%
Market cap:
$3.1B
Revenue:
$399.4M
EPS:
$-0.34
How Much Does Amicus Therapeutics Make?
-
How Much Are Amicus Therapeutics's Sales Annually?
FOLD Revenues are $399.4M -
How Much Profit Does Amicus Therapeutics's Make A Year?
FOLD net income is -$151.6M
Is Amicus Therapeutics Growing As A Company?
-
What Is Amicus Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.37% -
What Is Amicus Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Amicus Therapeutics Stock Price Performance
-
Did Amicus Therapeutics Stock Go Up Last Month?
Amicus Therapeutics share price went down by -1.14% last month -
Did FOLD's Share Price Rise Over The Last Year?
FOLD share price rose by 1.07% over the past 1 year
What Is Amicus Therapeutics 52-Week High & Low?
-
What Is Amicus Therapeutics’s 52-Week High Share Price?
Amicus Therapeutics has traded as high as $14.57 over the past 52 weeks -
What Is Amicus Therapeutics’s 52-Week Low Share Price?
Amicus Therapeutics has traded as low as $9.02 over the past 52 weeks
Amicus Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Amicus Therapeutics?
-
How Much Debt Does Amicus Therapeutics Have?
Total long term debt quarterly is $389.5M -
How Much Cash Does Amicus Therapeutics Have?
Cash and short term investments quarterly total is $249.8M -
What Is Amicus Therapeutics’s Book Value Per Share?
Book value per share is 0.60
Is Amicus Therapeutics Cash Flow Positive?
-
What Is FOLD Cash Flow From Operations?
Cash flow from operations (TTM) is -$26.5M -
What Is Amicus Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $12.2M -
What Is Amicus Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$4.1M
Amicus Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
FOLD return on invested capital is -19.5% -
What Is Amicus Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -13.78% -
What Is FOLD Return On Equity?
ROE is a measure of profitability and is -71.17%
Amicus Therapeutics Earnings Date & Stock Price
-
What Is Amicus Therapeutics's Stock Price Today?
A single share of FOLD can be purchased today for 10.38 -
What Is Amicus Therapeutics’s Stock Symbol?
Amicus Therapeutics trades on the nasdaq under the ticker symbol: FOLD -
When Is Amicus Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Amicus Therapeutics is scheduled on February 28, 2025 -
When Is FOLD's next ex-dividend date?
Amicus Therapeutics's next ex-dividend date is May 1, 2020 -
How To Buy Amicus Therapeutics Stock?
You can buy Amicus Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Amicus Therapeutics Competitors
-
Who Are Amicus Therapeutics's Competitors?
Below is a list of companies who compete with Amicus Therapeutics or are related in some way:
Amicus Therapeutics Dividend Yield
-
What Is FOLD Dividend Yield?
Amicus Therapeutics’s dividend yield currently is 0% -
What Is Amicus Therapeutics’s Payout Ratio?
Amicus Therapeutics’s payout ratio is 0% -
When Did Amicus Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 15, 2024 -
What Is Amicus Therapeutics’s Dividend Per Share?
Amicus Therapeutics pays a dividend of $0.00 per share
Amicus Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 91.02% |
Revenue: | 36.73% | 4.86% |
Analyst Recommendations
Buy Recommendations: | 9 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 17.75 |
Upside from Last Price: | 71% |